Coronavirus | In Tamil Nadu, 2,783 healthcare workers get immunised

In Tamil Nadu, 16.8% of healthcare suppliers took the COVID-19 vaccine on the primary day of immunisation on January 16.

The State has the capability to vaccinate 16,600 individuals a day however solely 2,783 received the shot on January 16 — probably the most in Chennai (348) and the least in Perambalur (2).

Also learn | Adequate stocks of vaccine for second dose on day 28 available, T.N. Health Secretary says

Vaccination was launched at 166 centres — the Serum Institute of India’s Covishield at 160 centres and Bharat Biotech’s Covaxin at six.

Each centre has the capability to vaccinate 100 individuals a day. A complete of two,684 of the deliberate 16,000 individuals took Covishield, whereas 99 of the 600 individuals opted for Covaxin.

In truth, two of the six centres that rolled out Covaxin — the Tirunelveli Medical College Hospital and the Mahatma Gandhi Memorial Medical College Hospital, Tiruchi — had no takers. No antagonistic occasion after immunisation was reported.

Also learn | Tamil Nadu CM inaugurates COVID-19 vaccination drive in Madurai

However, Health Department officers stated this was not a target-approach, however the train was primarily based on the willingness of healthcare suppliers. Several medical doctors, expressing apprehensions in regards to the vaccines, selected to attend and watch earlier than making a call. Health officers and hospital authorities hoped for an enchancment within the response from medical doctors within the coming days.

Chennai and Salem had probably the most variety of vaccination websites, with 12 every. In Chennai, 310 of the 1,200 healthcare suppliers/workers took Covishield. Salem adopted with 288 of the 1,200 individuals.

At Tiruppur, the vaccine was administered to 195 individuals, whereas in Madurai, the place the programme was launched by the Chief Minister, 146 of the whole 500 individuals took the vaccine. There have been 107 takers in Tiruvallur and 103 every in Cuddalore and Tiruvarur. Some of the districts that ended with the bottom figures have been Perambalur-2/100, Nagapattinam-10/400, Ariyalur-14/300, Ranipet-15/300, Kallakurichi-21/200 and Pudukottai-23/400.

Of the 99 individuals who opted for Covaxin, 40 obtained it on the Thanjavur Medical College Hospital, 38 on the Rajiv Gandhi Government General Hospital in Chennai, 20 on the Chengalpattu Medical College Hospital and one on the Pudukottai Medical College Hospital.

The vaccination took off throughout the State whilst many medical doctors selected to attend and watch earlier than making a call. “Most of the doctors at my hospital are not willing to get vaccinated. The hesitancy is mainly due to the fear about safety and the fact that these vaccines came about at such a short span of time,” a hospital authority stated.

A senior authorities physician in Chennai stated authorities struggled to get willingness from medical doctors and workers members till a day earlier than the vaccination. “Many staff moved away from the place when we asked whether they were willing to take the vaccine, while some others switched off their phones. We were struggling to get even 25 persons. But the response was good on the day of vaccination, and some want to come on Monday,” he stated.

A physician on the Government Medical College Hospital, Omandurar Government Estate, stated he may take the vaccine after every week. “Everyone prefers to wait and watch. Not many are enthusiastic about volunteering,” he stated. Another authorities physician of the Rajiv Gandhi Government General Hospital questioned how they may take the vaccines when the outcomes of the phase-3 trials have been but to be printed. “Scientifically, this is a wrong move. I still do not know why the government is launching the vaccines in haste,” he stated.

Many medical doctors objected to taking Covaxin. At the Rajiv Gandhi Government General Hospital, one of many six centres that supplied Covaxin, 38 medical doctors took the vaccine. Among them have been the Dean, two administrators, 4 professors and 20 workers members of two Indian Council of Medical Research institutes — the National Institute for Research in Tuberculosis and the National Institute of Epidemiology.

The screening and consent type for Covaxin stated, “In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antibodies against COVID-19. However, the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase 3 clinical trial. Hence, it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed.”